Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Albireo Pharma stock

Learn how to easily invest in Albireo Pharma stock.

Albireo Pharma is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 130 staff and has a trailing 12-month revenue of around $57.4 million.

How to buy Albireo Pharma stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ALBO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Albireo Pharma stock price (NASDAQ: ALBO)

Use our graph to track the performance of ALBO stocks over time.

Albireo Pharma shares at a glance

Information last updated 2023-02-01.
Latest market close$44.59
52-week range$16.02 - $44.75
50-day moving average $28.12
200-day moving average $23.82
Wall St. target price$43.80
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.70

Buy Albireo Pharma stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Albireo Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Albireo Pharma price performance over time

Historical closes compared with the close of $44.59 from 2023-02-06

1 week (2023-01-31) -0.16%
1 month (2023-01-06) 95.40%
3 months (2022-11-07) 99.24%
6 months (2022-08-05) 69.09%
1 year (2022-02-07) 43.84%
2 years (2021-02-05) 6.29%
3 years (2020-02-07) 95.74%
5 years (2018-02-06) 28.46%

Albireo Pharma financials

Revenue TTM $57.4 million
Gross profit TTM $39.2 million
Return on assets TTM -24.94%
Return on equity TTM -93.08%
Profit margin -228.51%
Book value $4.84
Market capitalisation $926.9 million

TTM: trailing 12 months

Albireo Pharma share dividends

We're not expecting Albireo Pharma to pay a dividend over the next 12 months.

Have Albireo Pharma's shares ever split?

Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.

Albireo Pharma share price volatility

Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $16.02 up to $44.75. A popular way to gauge a stock's volatility is its "beta".

ALBO.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 0.7119. This would suggest that Albireo Pharma's shares are less volatile than average (for this exchange).

Albireo Pharma overview

Albireo Pharma, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.

Frequently asked questions

What percentage of Albireo Pharma is owned by insiders or institutions?
Currently 3.505% of Albireo Pharma shares are held by insiders and 98.429% by institutions.
How many people work for Albireo Pharma?
Latest data suggests 130 work at Albireo Pharma.
When does the fiscal year end for Albireo Pharma?
Albireo Pharma's fiscal year ends in December.
Where is Albireo Pharma based?
Albireo Pharma's address is: 10 Post Office Square, Boston, MA, United States, 02109
What is Albireo Pharma's ISIN number?
Albireo Pharma's international securities identification number is: US01345P1066
What is Albireo Pharma's CUSIP number?
Albireo Pharma's Committee on Uniform Securities Identification Procedures number is: 09064M105

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site